Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE1831 in IgG4-related disease (Phase Ib/IIa, China)
CTR20260352Phase 2Active
- Sponsor
- EyeBio
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ACE1831 in IgG4-related disease (IgG4-RD), sponsored by EyeBio. Started Feb 2026; status: active.
02
Drugs
ACE1831
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on CTR20260352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260352.